Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
First Claim
1. A method for manufacturing delivery devices for the transdermal administration of a liquid drug capable of forming a crystalline hydrate which comprises, in combination:
- a. forming a laminate, at least one lamina of which comprises a dispersion of said liquid drug in a nonaqueous matrix;
b. cutting subunits forming said delivery devices from said laminate;
c. packaging said delivery devices in sealed containers;
d. heating said delivery devices in said containers to a temperature above the melting point of said crystalline hydrate and maintaining said delivery devices at such temperature for a time sufficient to prevent the formation of said crystalline hydrate for a substantial period of time after cooling of the subunits to ambient temperatures; and
e. cooling the delivery devices to ambient conditions.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for preventing the formation of crystalline hydrates in a dispersion of a hydratable liquid in a nonaqueous matrix is disclosed. The method is particularly useful in the manufacture of laminated items formed from such dispersions and comprises forming individual subunits from such dispersions, heating the subunits, preferably after they have been packed in sealed containers, to a temperature high enough to melt the crystalline hydrate, maintaining said subunits at such temperature for a time sufficient to melt all the crystalline hydrate present and to prevent the occurrence of crystals for an extended period of time after cooling and cooling subunits to ambient conditions. The use of the method in the manufacture of transdermal delivery devices for the delivery of scopolamine base is described.
80 Citations
24 Claims
-
1. A method for manufacturing delivery devices for the transdermal administration of a liquid drug capable of forming a crystalline hydrate which comprises, in combination:
-
a. forming a laminate, at least one lamina of which comprises a dispersion of said liquid drug in a nonaqueous matrix; b. cutting subunits forming said delivery devices from said laminate; c. packaging said delivery devices in sealed containers; d. heating said delivery devices in said containers to a temperature above the melting point of said crystalline hydrate and maintaining said delivery devices at such temperature for a time sufficient to prevent the formation of said crystalline hydrate for a substantial period of time after cooling of the subunits to ambient temperatures; and e. cooling the delivery devices to ambient conditions. - View Dependent Claims (2, 3, 11, 12, 13)
-
-
4. A process for manufacturing delivery devices for the transdermal administration of scopolamine base which comprise in combination:
-
a. forming a laminate, at least one lamina of which comprises a dispersion of said scopolamine base in a nonaqueous matrix; b. cutting subunits forming said delivery devices from said laminate; c. packaging said delivery devices in sealed containers; d. heating said delivery devices in said containers to a temperature above the melting point of crystalline scopolamine hydrate and maintaining said delivery devices at such temperature for a time sufficient to prevent the formation of said crystalline hydrate for a substantial period of time after cooling of the subunits to ambient temperatures; and e. cooling the delivery devices to ambient conditions. - View Dependent Claims (5, 6, 7, 8, 14, 15, 16)
-
-
9. A process for preventing the formation of the crystalline hydrate of a liquid material dispersed within a non-aqueous matrix which comprises, in combination:
-
a. forming a laminate, at least one lamina of which comprises a dispersion of a hydratable liquid in a matrix; b. cutting subunits from said laminate; c. packaging the individual subunits in sealed containers; d. heating said subunits in said packages to an elevated temperature and maintaining said subunits at said elevated temperature for a time sufficient to prevent the formation of said crystalline hydrate for a substantial period of time after cooling of the subunits to ambient temperatures; and e. cooling the subunits to ambient conditions. - View Dependent Claims (10, 17, 18)
-
-
19. A process for producing laminated structure within a sealed container which comprises:
-
a. forming a laminated structure, at least one lamina of which comprises a dispersion of a liquid capable of forming a crystalline hydrate in a nonaqueous matrix; and b. packaging said laminated structure in a sealed container; c. heating said laminated structure in said sealed container to an elevated temperature and maintaining said structure at said elevated temperature for a period of time sufficient to prevent formation of said crystalline hydrate for a substantial period of time after cooling of said laminated structure to ambient temperatures; and d. cooling said laminated structure in said sealed container to ambient temperatures.
-
-
20. In a process for producing a laminated structure within a sealed container which comprises:
-
a. forming a laminated structure, at least one lamina of Which comprises a dispersion of a liquid capable of forming a crystalline hydrate in a nonaqueous matrix; and b. packaging said subunits in a sealed container;
the improvement which comprises;c. heating said laminated structure in said sealed container to an elevated temperature; d. maintaining said structure at said elevated temperature for a period of time sufficient to prevent formation of said crystalline hydrate for a substantial period of time after cooling of said laminated structure to ambient temperatures; and e. cooling said laminated structure in said sealed container to ambient temperatures. - View Dependent Claims (21)
-
-
22. A process for producing a laminated dosage form of scopolamine packaged within a sealed container which comprises:
-
a. forming a laminated dosage form of scopolamine, at least one lamina of which comprises a dispersion of a liquid scopolamine base in a nonaqueous matrix; and b. packaging said dosage form in a sealed container;
the improvement which comprises;c. heating said dosage form in said sealed container to an elevated temperature; d. maintaining said dosage form at said elevated temperature for a period of time sufficient to prevent formation of a crystalline of scopolamine base for a substantial period of time after cooling of said dosage form to ambient temperatures; and e. cooling said dosage form in said sealed container to ambient temperatures. - View Dependent Claims (23, 24)
-
Specification